Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Karl D. Lewis, MD, on Selecting Patients for Treatment With Cemiplimab-rwlc

Posted: Monday, October 14, 2019

For which patients with cutaneous squamous cell carcinoma would you consider treatment with an anti–PD-1 antibody such as cemiplimab-rwlc?



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.